NCT07436416Completed
Circulating and Urinary Exosomal miRNA as Predictors of Treatment Response in Advanced Kidney Cancer
The Role of Monitoring of the Circulating and Urinary Exosomal miRNA for Prediction of Response to Treatment in Patients With Advanced Kidney Cancer (EXO-RENAL2)
Source: ClinicalTrials.gov · Last updated 27 Feb 2026
Brief summary (registry, in English)
This study investigates the role of circulating and urinary exosomal microRNAs (miRNAs) as potential biomarkers for predicting response to systemic therapy in patients with advanced renal cell carcinoma. Patients receiving immune checkpoint inhibitors or targeted therapies are followed during the first 16 weeks of treatment. Blood and urine samples are collected at predefined time points for analysis of exosome-associated miRNAs. Imaging assessments are performed as part of routine clinical follow-up. The aim of the study is to identify exosomal miRNA profiles associated with treatment response and to support the development of non-invasive predictive biomarkers in advanced kidney cancer.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 91 (actual)
- First submitted
- 12 Feb 2026
- Start date
- 1 Mar 2022
- Primary completion date
- 31 Dec 2022
- Lead sponsor
- Institute of Oncology Ljubljana
- Diseases
- Kidney cancer
- NCT number
- NCT07436416
What you commit to
- Study type: Interventional
- Participants enrolled: 91
- From 1 Mar 2022 to the primary completion date, 31 Dec 2022
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Any condition preventing participation according to investigator assessment
Age
- Age \<18 years
Other
- Inability to provide required blood and urine samples
- Inability to provide informed consent
Who the study is looking for
- Adults (≥18 years)
- Histologically confirmed advanced or metastatic renal cell carcinoma
- Receiving systemic treatment with immune checkpoint inhibitors and/or targeted therapy (first- or second-line therapy)
- Ability to provide blood and urine samples according to the study protocol
- Written informed consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Institute of Oncology Ljubljana Coordinator of this site? Confirm its status | Ljubljana | Slovenia | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.